ArticleBMJ (Clinical research ed.)2003

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

Jim Chilcott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.